Clinical Trial

A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose (RP2D) of ES014 by evaluating the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of ES014 administered intravenously to subjects with advanced solid tumors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-01-28; most recent amendment 2025-08-11.
Status change: Recruiting → Active, Not Recruiting 2025-06-20
Status change: Not Yet Recruiting → Recruiting 2023-02-27
Trial Details
NCT Number NCT05717348
Lead Sponsor Elpiscience (Suzhou) Biopharma, Ltd.
Conditions Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor
Enrollment 120 participants
Start Date 2023-02-24
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-08-13